
Opinion|Videos|September 27, 2024
Treatment Landscape for Transplant-Eligible Patients with NDMM
Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Provide a brief overview of first-line treatment options currently available for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Semaglutide Shows Direct Organ-Protective Benefits Beyond Weight Loss in HFpEF
2
November 2025 Pharmacy Policy Updates
3
Recapping TMS 2025: Evolving Insights and Future Directions in Menopause Care
4
Immune Synergy May Explain Why Some Patients Achieve Durable Remission With Cilta-Cel
5















































































































































































































